The applicant, including all corporate officers, must be fingerprinted at a law enforcement agency. The law enforcement agency, not the applicant, must send the fingerprint sheet to the Department (80-18-103, MCA). Most local law enforcement offices provide fingerprinting services. The completed application and copy of the law enforcement submitted fingerprints will be submitted for DEA review and approval. The DEA may place additional requirements on the Department or the applicant for participation or continuation of the program. At the end of the licensure, program participants must submit an agricultural/agronomic report regarding their experience with their hemp crop. The report shall include the approximate yield in pounds per acre and the method used to devitalize the seed. All seed must be devitalized after harvest and no seed production for future planting is allowed under the Montana Industrial Hemp Pilot Program.
The Department has policies and procedures in place for the commonwealth's hemp research program, which can be found in the 2019 Pilot Program Parameters. Researchers from institutions of higher education or growers who would like to be considered for participation in the 2019 program must submit a 2019 PDA Industrial Hemp Research Pilot Program Permit Application prior to the application deadline of December 17, 2018. Researchers who participated in the 2018 Pilot Program may submit a Permit Renewal form by December 17, 2018 to continue their projects in the 2019 growing season.
According to the United States Department of Health and Human Services, there were 455,000 emergency room visits associated with cannabis use in 2011. These statistics include visits in which the patient was treated for a condition induced by or related to recent cannabis use. The drug use must be "implicated" in the emergency department visit, but does not need to be the direct cause of the visit. Most of the illicit drug emergency room visits involved multiple drugs. In 129,000 cases, cannabis was the only implicated drug.
The genus Cannabis was first classified using the "modern" system of taxonomic nomenclature by Carl Linnaeus in 1753, who devised the system still in use for the naming of species. He considered the genus to be monotypic, having just a single species that he named Cannabis sativa L. (L. stands for Linnaeus, and indicates the authority who first named the species). Linnaeus was familiar with European hemp, which was widely cultivated at the time. In 1785, noted evolutionary biologist Jean-Baptiste de Lamarck published a description of a second species of Cannabis, which he named Cannabis indica Lam. Lamarck based his description of the newly named species on plant specimens collected in India. He described C. indica as having poorer fiber quality than C. sativa, but greater utility as an inebriant. Additional Cannabis species were proposed in the 19th century, including strains from China and Vietnam (Indo-China) assigned the names Cannabis chinensis Delile, and Cannabis gigantea Delile ex Vilmorin. However, many taxonomists found these putative species difficult to distinguish. In the early 20th century, the single-species concept was still widely accepted, except in the Soviet Union where Cannabis continued to be the subject of active taxonomic study. The name Cannabis indica was listed in various Pharmacopoeias, and was widely used to designate Cannabis suitable for the manufacture of medicinal preparations.
Going forward, another emerging trend among recreational users are wellness lifestyles built around cannabis. This is certainly part of the influence of California’s new recreational marijuana market, which went online January 1, 2018. California is already an epicenter for health and wellness lifestyles and fads. Expect to see more of the same now that cannabis is completely legal.
Cannabis has mental and physical effects such as creating a "high" or "stoned" feeling, a general change in perception, heightened mood, and an increase in appetite. Onset of effects is within minutes when smoked, and about 30 to 60 minutes when cooked and eaten. They last for between two and six hours. Short-term side effects may include a decrease in short-term memory, dry mouth, impaired motor skills, red eyes, and feelings of paranoia or anxiety. Long-term side effects may include addiction, decreased mental ability in those who started as teenagers, and behavioral problems in children whose mothers used cannabis during pregnancy. Studies have found a strong relation between cannabis use and the risk of psychosis, though the cause-and-effect relationship is debated.
In 2013, BMW announced its newest electric car, the i3. Using low-weight hemp in its interior, the i3 weighs 800 pounds less than its market competitors. The Kestrel, created by Canadian Motive Industries, uses polymer resin-infused hemp stalks to replace fiberglass in the body of the vehicle. From this replacement, consumers can expect a dramatic reduction in weight, improved efficiency and the appeal of an ecologically sustainable vehicle.
But there’s a big difference between the two. Hemp seed oil has been pressed from hemp seed, and it’s great for a lot of things – it’s good for you, tastes great, and can be used in soap, paint – even as biodiesel fuel. However, hemp seed oil does not contain any concentration of cannabinoids at all, including CBD. So by all means, stock up at your local natural food store. Just don’t expect to reap the benefits of a true CBD oil when you cook with hemp seed oil.
A limited number of studies have examined the effects of cannabis smoking on the respiratory system. Chronic heavy marijuana smoking is associated with coughing, production of sputum, wheezing, and other symptoms of chronic bronchitis. The available evidence does not support a causal relationship between cannabis use and chronic obstructive pulmonary disease. Short-term use of cannabis is associated with bronchodilation.
CBD oil 4% is a medium-strength, organic formulation. Now, you can supplement with the confidence of a king or queen! If you are already familiar with CBD and find you require a little more than what's offered by our 2.5% formulation, this is the CBD oil for you. CBD oil 4% is derived from EU hemp strains bred for a high CBD content. Natural, GMO-free, and non-psychoactive. Available now in convenient 10, 30 and 50ml dropper bottles.
State legislatures have taken action to promote industrial hemp as an agricultural commodity in recent years. A wide range of products, including fibers, textiles, paper, construction and insulation materials, cosmetic products, animal feed, food, and beverages all may use hemp. The plant is estimated to be used in more than 25,000 products spanning nine markets: agriculture, textiles, recycling, automotive, furniture, food/nutrition/beverages, paper, construction materials and personal care.
There’s also been a lot of talk lately about “microdosing” CBD. This refers to an incremental process of finding your minimum effective dose. You can do this with any concentration of CBD oil, but lower concentrations will take longer. In a 2017 article in Rolling Stone, Dr. Dustan Sulak outlines his protocol for microdosing. You can begin this process by asking yourself three questions:
Neurologists are skilled at predicting side effects and interactions between well-researched pharmaceuticals. But due to the dearth of reliable research about CBD, doctors like Hernandez and Knupp cannot guide their patients in its use. If there are adverse reactions, Penny will find out because Harper will suffer through them. She has had to figure out through trial and error how best to mix and measure Harper’s oils. The bottom line, Penny said, is simple: “We are the research.”
"CBD increases the circulating levels of your natural endocannabinoids, which, in turn, interact with your cannabinoid receptors," Bonn-Miller says. "CBD has also been shown to interact with serotonin receptors, and that may be part of why it has some beneficial effects on anxiety. It also interacts with some pain receptors, which may be why we're starting to see effects on pain and inflammation."
^ Jump up to: a b Weinstein A, Livny A, Weizman A (2016). "Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users". Current Pharmaceutical Design. 22 (42): 6366–6379. doi:10.2174/1381612822666160822151323. PMID 27549374. 1)The studies reviewed so far demonstrated that chronic cannabis use has been associated with a volume reduction of the hippocampus...3)The overall conclusion arising from these studies is that recent cannabis users may experience subtle neurophysiological deficits while performing on working memory tasks, and that they compensate for these deficits by "working harder" by using additional brain regions to meet the demands of the task.
In recent years, a wide range of synthetic products, claiming to have similar effects to cannabis, have also been available in Australia. Synthetic cannabis is made up of chemicals that are designed to activate the same chemical systems in the brain as THC. These drugs are marketed as having similar physical and psychological effects as cannabis, but can have more unpredictable effects and are potentially more harmful than cannabis.
The main difference between the two is in its chemical composition, specifically in tetrahydrocannabinol (THC). THC is the chemical responsible marijuana’s psychological effects.An average batch of marijuana contains anywhere from 5-20% THC content. Some premium marijuana can have up to 25-30% THC. Hemp, on the other hand, has a max THC level of 0.3%, essentially making it impossible to feel any psychoactive effect or get a “high”. This threshold is heavily regulated in other countries that have legalized hemp.Hemp also has high cannabidiol (CBD) content that acts as THC’s antagonist, essentially making the minimal amount of THC useless.
Pain management improves a patient’s quality of life throughout all stages of cancer. Through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced analgesia have been analyzed.[Level of evidence:1iC] The CB1 receptor is found in the central nervous system (CNS) and in peripheral nerve terminals. CB2 receptors are located mainly in peripheral tissue and are expressed in only low amounts in the CNS. Whereas only CB1 agonists exert analgesic activity in the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.[48,49]